Navidea Biopharmaceuticals Inc is a biotechnology company specialized in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products, are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
| Website: | www.navidea.com |
| Email: | jlatkin@navidea.com |
| Main Phone: | +1 614 793-7500 |
| Address: | 4995 Bradenton Avenue |
| Address 2: | Suite 240 |
| State: | OH |
| City / Town: | Dublin |
| Country: | USA |
| Postal Code: | 43017-3552 |
| Exchange: | AMX |
| CEO: | Jed A. Latkin |
| Employees: | 24 |
| NAICS: | In-Vitro Diagnostic Substance Manufacturing(325413) |
Gathering Data... Please wait Navidea Biopharmaceuticals Inc is a biotechnology company specialized in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products, are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
| Website: | www.navidea.com |
| Email: | jlatkin@navidea.com |
| Main Phone: | +1 614 793-7500 |
| Address: | 4995 Bradenton Avenue |
| Address 2: | Suite 240 |
| State: | OH |
| City / Town: | Dublin |
| Country: | USA |
| Postal Code: | 43017-3552 |
| Exchange: | AMX |
| CEO: | Jed A. Latkin |
| Employees: | 24 |
| NAICS: | In-Vitro Diagnostic Substance Manufacturing(325413) |
| Last Price 0.14 | Change $ 0.006111 | Change % 4.74 | Tick N/A |
| Bid 0.14 | Bid Size 6,200.00 | Ask 0.14 | Ask Size 3,400.00 |
| Open 0.13 | High 0.15 | Low 0.13 | Prev Close 0.13 |
| Last Trade | Volume 268,268 | 52 Wk Hi 0.41 | 52 Wk Low 0.10 |
| Market Cap 24.6 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 181,890,700.00 | EPS (TTM) -0.10 | PE Ratio N/A | Exchange NYSE American |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 1 | 11 |
| Number of Buys | 1 | 10 |
| Number of Sells | 0 | 1 |
| Net Activity | 50000 | 527694 |
| Last 10 Buys | Shares |
|---|---|
| William J. Regan | 1,000 |
| Jed A. Latkin | 1,000 |
| Jed A. Latkin | 1,000 |
| Jed A. Latkin | 1,000 |
| Gordon A. Troup | 1,000 |
| Brendan A. Ford | 1,000 |
| Michael M. Goldberg | 1,000 |
| Michael M. Goldberg | 1,000 |
| Brendan A. Ford | 1,000 |
| Mark J. Pykett | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Brent L. Larson | 1,000 |
| Frederick O. Cope | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 2.4 | 2.4 | 2.4 | 2.4 |
| Low Target Price Estimate | 2.4 | 2.4 | 2.4 | 2.4 |
| Mean Target Price Estimate | 2.4 | 2.4 | 2.4 | 2.4 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 04/05/16 | 04/05/16 | 04/05/16 | 04/05/16 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| PRE 14A | Preliminary proxy statement providing notification matters to be brought to a vote | 75 | 2018-06-07 |
| SD | Specialized Disclosure Report | 2 | 2018-05-31 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 52 | 2018-05-09 |
| 8-K | Report of unscheduled material events or corporate changes. | 9 | 2018-05-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-04-04 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-04-02 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-16 |
| 10-K | Annual report with a comprehensive overview of the company | 135 | 2018-03-15 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-03-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 9 | 2018-03-08 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 0 | 0 | 0 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
